No difference in survival between sporadic, familial and hereditary prostate cancer

Abstract

Objective To estimate the survival of men with familial prostate cancer and compare them with prostate cancer cases unselected for family history. Patients and methods The overall and prostate cancer‐specific survival was calculated in two large (249 and 304 men, respectively) population‐based cohorts of men with familial prostate cancer. The tumour grade at diagnosis was also obtained in one of the cohorts. Results There were no significant differences in either overall or prostate cancer‐specific survival between familial and sporadic cases. The spectrum of tumour grades at diagnosis in familial cases did not differ from that in a population with prostate cancer unselected for family history. Conclusion No differences in treatment between men with or without a positive family history of prostate cancer are justified, based on the result from this study.

Genetic Determinants of Prostate Cancer: A Review

“…Over 65 months there was no difference in pathological features or progression interval 22 . Hanlon 23 retrospectively evaluated 920 men after radiotherapy without neoadjuvant hormonal treatment where 97 of the men fulfilled the criteria for familial or hereditary PC. Although the follow-up was relatively short, there were no differences in terms of frequency or time to biochemical failure.…”

Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?

“…Studies have focused on the number of tumors, Gleason score, pathologic stage, and biochemical DFS and cancer-specific survival rates (1,(5)(6)(7)(8)(9). However, there is very little information about the zonal distribution of prostate cancer in patients with a positive family history.…”

“…In this study, patients with sporadic PC had a mean 7.3 tumor foci per Although patients with a positive family history of PC are at higher risk of developing the disease, most studies suggest that these patients have either equivalent (12) or more favorable disease characteristics, such as lower Gleason scores (1,7,21) or less extracapsular tumor extension (9). Furthermore, there is no convincing evidence that survival is better or worse for patients with a positive family history of PC undergoing RP (5,8,9) or primary radiation therapy (22) compared to patients with sporadic PC. Surprisingly, only one group reported differences in biochemical DFS following RP or primary radiation therapy favoring patients with sporadic PC.…”

“…Whereas a number of earlier studies evaluated family history and radical prostatectomy (RP) pathology to determine the significance of a positive family history as a risk factor for PC, they were directed largely at the number of tumors, the pathologic stage, and outcome measures including biochemical disease-free survival (DFS) and overall survival (5)(6)(7)(8)(9). Very little information is available on the zonal distribution of cancers in patients with a positive family history.…”

Genetic Epidemiology of Hereditary Prostate Cancer in Finland

“…Three formal segregation analyses have been published (Carter et al 1992). All these have suggested an autosomal dominant mode of inheritance of rare (population frequency 0.3 -1.7%) high risk allele, conferring 63 -89 % risk of prostate cancer by age of 85 years (Carter et al, 1992;Grönberg et al, 1998;Schaid et al, 1998) (Table 3, page 22). In the study by Carter and co-workers (1992) the risk of prostate cancer for heterozygous carriers of prostate cancer risk allele was estimated to be 88% by the age of 85 years, as compared to 5% for noncarriers.…”